In comparison to having no cancer genetic services the clinical strategy of having both a mastectomy and an oophorectomy provided almost no incremental QALYs for high-risk BRCA1/2 mutation carriers (0.003 QALYs) and was inferior for high-risk carriers of unidentified mutations (−0.55 QALYs). This evidence concerns the gene BRCA1 and cancer.